ウィメンズヘルス向け治療の技術と世界市場

Report Highlights

The global therapeutics for women’s health technologies market is expected to grow from $61.5 billion in 2024 and is projected to reach $81.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.7% during the forecast period of 2024 to 2029.

ウィメンズヘルス向け治療の技術の世界市場は、2024年の615億ドルから2024年から2029年の予測期間中に5.7%の複合年間成長率（CAGR）で成長し、2029年末までに812億ドルに達すると予測されています。

Summary

The factors driving market growth are the growing population of older women and the rising awareness of and accessibility to healthcare and advanced therapeutic products. High treatment costs and regulatory challenges are restraining the market’s growth.

In 2023, the breast cancer segment of the global therapeutics for women’s health technologies held the largest share, 55.1% of the market segmented by women’s health disorders, and this segment is expected to grow at a CAGR of 5.9% during the forecast period.

Report Scope

This report provides a detailed analysis of the global therapeutics for women’s health technologies market, including coverage of market drivers, restraints and opportunities. It also includes analyses of this market’s competitive environment and products. The report presents market estimates and forecasts for women’s health therapeutics and provides market projections through 2029. For this analysis, the market is segmented by conditions related to women’s health, including breast cancer, postmenopausal osteoporosis, menopause, endometriosis and polycystic ovary syndrome (PCOS), and by geographic region. The report provides company profiles of the market’s leading players that feature detailed information about each company’s business segments, financials, product portfolios and recent developments.

このレポートは、ウィメンズヘルス向け治療の技術の世界市場の詳細な分析を提供し、市場の推進要因、制約、機会を網羅しています。また、この市場の競争環境と製品の分析も含まれています。レポートでは、女性の健康治療薬の市場推定と予測を示し、2029年までの市場予測を提供します。この分析では、市場は乳がん、閉経後骨粗鬆症、更年期障害、子宮内膜症、多嚢胞性卵巣症候群（PCOS）などの女性の健康に関連する症状と地域別にセグメント化されています。レポートでは、市場の主要企業の企業プロファイルを提供し、各企業の事業セグメント、財務、製品ポートフォリオ、最近の開発に関する詳細情報を取り上げています。

By region, the global therapeutics for women’s health technologies market is segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes the U.K., Germany, Spain, France, Italy and the Rest of Europe; Asia-Pacific comprises China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. The rest of the World includes the Middle East and Africa, and South America. In the report’s market estimates, 2021 and 2022 serve as historical years, 2023 as the base year, and data forecasts are given through 2029.

地域別に見ると、ウィメンズヘルス向け治療の技術の世界市場は、北米、ヨーロッパ、アジア太平洋、その他の地域（RoW）に区分されています。北米地域には、米国、カナダ、メキシコが含まれます。ヨーロッパには、英国、ドイツ、スペイン、フランス、イタリア、その他のヨーロッパが含まれます。アジア太平洋地域には、中国、日本、インド、オーストラリア、韓国、その他のアジア太平洋地域が含まれます。その他の地域には、中東、アフリカ、南米が含まれます。レポートの市場予測では、2021年と2022年が過去年、2023年が基準年となり、2029年までのデータ予測が示されています。

Report Synopsis

Report Includes

– 46 data tables and 63 additional tables

– An overview of the global market and technologies for women’s health therapeutics

– Analyses of the global market trends, with sales data for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029

– Study of women’s diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS), including their historical background, stages, symptoms, risk factors -and genetic factors, diagnosis, and treatment options

– Discussion on aging and women’s health disorders, women and sexual health such as female sexual arousal disorder, female orgasmic disorder and vaginismus, as well as the relationship between infertility and cancer

– Information about significant products, companies, issues and trends affecting the women’s disorders and diseases industry

– Evaluation of the impact of demographic, economic and other factors that will drive demand in the market for women’s health therapeutics

– Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials

– Identification of the market drivers, restraints and other forces impacting the global market, as well as an evaluation of current and projected market size

– A discussion of ESG challenges and practices in the industry

– Market share analysis of the key companies and coverage of their proprietary technologies, strategic alliances, and other market strategies

– Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Pfizer Inc., Eli Lilly and Company, Novartis AG and Amgen Inc.

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Insights

Chapter 2 Market Overview

Overview

Definitions

Breast Cancer

Postmenopausal Osteoporosis

Menopause

Endometriosis

Polycystic Ovary Syndrome (PCOS)

Historical Context

Aging and Women’s Health Disorders

Chapter 3 Market Dynamics

Overview

Market Drivers

Rising Population of Older Women

Increasing Awareness and Accessibility

Market Restraints

High Treatment Costs

Regulatory Challenges

Market Opportunities

Advances in Personalized Medicine

Emerging Markets

Chapter 4 Emerging Technologies

Overview

Digital Health Solutions

Advanced Fertility Technologies

Targeted Biologics and Biosimilars

Nanotechnology-Driven Drug Delivery

Gene Therapy and CRISPR

Chapter 5 Pipeline Assessment and Analysis

Overview

Women’s Health Therapeutics: Key Clinical Trial Developments

Drugs in Pipeline

Overview of Osteoporosis Drug Development Pipeline

Chapter 6 Regulatory Structure

Overview of Regulations

U.S.

Drug Development and Approval Process

Types of Applications Reviewed by FDA

Canada

Food and Drugs Act (F-27)

Europe

Japan

Chapter 7 Market Segmentation Analysis

Segmentation Breakdown

Market Analysis, by Women’s Health Disorder

Breast Cancer

Postmenopausal Osteoporosis

Menopause

Endometriosis

PCOS

Geographic Breakdown

Market Analysis, by Region

North America

Europe

Asia-Pacific

Rest of the World

Chapter 8 Competitive Landscape

Overview

Market Players and Strategies

Patent Analysis

Key Developments

Chapter 9 ESG Perspective

Introduction to ESG

ESG Goals for the Pharmaceutical Sector

Focus on Energy Efficiency

Reduce Emissions and Carbon Footprint

Waste Generation and Disposal

Manufacturing, Distribution and Transportation

Social Responsibility

Governance

ESG Risk Ratings in the Pharmaceutical Industry

Concluding Remarks from BCC Research

Chapter 10 Appendix

Methodology

Sources

Abbreviations

Company Profiles

ABBVIE INC.

AMGEN INC.

ASAHI KASEI CORP.

ASTRAZENECA

BAYER AG

BRISTOL-MYERS SQUIBB CO.

EISAI CO. LTD.

HOFFMANN-LA ROCHE LTD.

JOHNSON & JOHNSON SERVICES INC.

LILLY

MERCK & CO. INC.

NOVARTIS AG

NOVO NORDISK A/S

PFIZER INC.

TEVA PHARMACEUTICAL INDUSTRIES LTD.

List of Tables

Summary Table : Global Therapeutics for Women’s Health Technologies Market, by Region, Through 2029

Table 1 : Significant Events in Women’s Health History in the U.S., 1983-Post-2000

Table 2 : Key Clinical Trial Developments, 2024

Table 3 : Novel Breast Cancer Drug Approvals, 2020

Table 4 : Pipeline Drugs for Treating Endometriosis

Table 5 : Pipeline Drugs for Treating Uterine Fibroids

Table 6 : Pipeline Drugs for Treating Osteoporosis

Table 7 : Key European Regulations and Directives Impacting Women’s Health

Table 8 : Global Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 9 : Factors That Increase the Relative Risk for Invasive Breast Cancer in Women

Table 10 : TNM Classification of Breast Cancers

Table 11 : Drugs Commonly Used to Treat Breast Cancer

Table 12 : Global Breast Cancer Market in Therapeutics for Women’s Health, by Region, Through 2029

Table 13 : Global Postmenopausal Osteoporosis Market in Therapeutics for Women’s Health, by Region, Through 2029

Table 14 : FDA-Approved Estrogen-Only Medicines

Table 15 : FDA-Approved Progestin-Only Medicines

Table 16 : FDA Approved Combination, Estrogen and Progestin Medicines

Table 17 : FDA-Approved Combination Estrogen and Hormone Medicines

Table 18 : Global Menopause Market in Therapeutics for Women’s Health, by Region, Through 2029

Table 19 : Global Endometriosis Market in Therapeutics for Women’s Health, by Region, Through 2029

Table 20 : Commonly Prescribed Generic Drugs for the Treatment of PCOS

Table 21 : Global PCOS Market in Therapeutics for Women’s Health, by Region, Through 2029

Table 22 : Global Therapeutics for Women’s Health Technologies Market, by Region, Through 2029

Table 23 : North American Therapeutics for Women’s Health Technologies Market, by Country, Through 2029

Table 24 : North American Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 25 : U.S. Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 26 : Canadian Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 27 : Mexican Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 28 : European Therapeutics for Women’s Health Technologies Market, by Country, Through 2029

Table 29 : European Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 30 : German Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 31 : U.K. Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 32 : French Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 33 : Italian Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 34 : Spanish Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 35 : Rest of European Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 36 : Asia-Pacific Therapeutics for Women’s Health Technologies Market, by Country, Through 2029

Table 37 : Asia-Pacific Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 38 : Chinese Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 39 : Japanese Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 40 : Indian Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 41 : Australian Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 42 : South Korean Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 43 : Rest of APAC Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 44 : Rest of the World Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029

Table 45 : Leading Companies in Therapeutics for Women’s Health Technologies, 2023

Table 46 : Major Women’s Health Therapeutics Pharmaceuticals, 2023

Table 47 : Active Patents of Key Competitor Companies, 2024

Table 48 : Approvals for Novel Drugs for Therapeutics for Women’s Health Technologies, 2021

Table 49 : Selected New Women’s Health Therapeutic Drugs in Late Stages of Clinical Development

Table 50 : ESG Rankings for Leading Players in Therapeutics for Women’s Health Technologies Market, 2024

Table 51 : Information Sources in This Report

Table 52 : Glossary of Terms Used in the DNA Sequencing Market

Table 53 : AbbVie Inc.: Company Snapshot

Table 54 : AbbVie Inc.: Financial Performance, FY 2022 and 2023

Table 55 : AbbVie Inc.: Product Portfolio

Table 56 : AbbVie Inc.: News/Key Developments, 2022

Table 57 : Amgen Inc.: Company Snapshot

Table 58 : Amgen Inc.: Financial Performance, FY 2022 and 2023

Table 59 : Amgen Inc.: Product Portfolio

Table 60 : Amgen Inc.: News/Key Developments, 2023

Table 61 : Asahi Kasei Corp.: Company Snapshot

Table 62 : Asahi Kasei Corp.: Financial Performance, FY 2022 and 2023

Table 63 : Asahi Kasei Corp.: Product Portfolio

Table 64 : AstraZeneca: Company Snapshot

Table 65 : AstraZeneca: Financial Performance, FY 2022 and 2023

Table 66 : AstraZeneca: Product Portfolio

Table 67 : AstraZeneca: News/Key Developments, 2023 and 2024

Table 68 : Bayer AG: Company Snapshot

Table 69 : Bayer AG: Financial Performance, FY 2022 and 2023

Table 70 : Bayer AG: Product Portfolio

Table 71 : Bayer AG: News/Key Developments, 2024

Table 72 : Bristol-Myers Squibb Co.: Company Snapshot

Table 73 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023

Table 74 : Bristol-Myers Squibb Co.: Product Portfolio

Table 75 : Eisai Co. Ltd.: Company Snapshot

Table 76 : Eisai Co. Ltd.: Financial Performance, FY 2022 and 2023

Table 77 : Eisai Co. Ltd.: Product Portfolio

Table 78 : F. Hoffmann-La Roche Ltd.: Company Snapshot

Table 79 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023

Table 80 : F. Hoffmann-La Roche Ltd.: Product Portfolio

Table 81 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023 and 2024

Table 82 : Johnson & Johnson Services Inc.: Company Snapshot

Table 83 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023

Table 84 : Johnson & Johnson Services Inc.: Product Portfolio

Table 85 : Lilly: Company Snapshot

Table 86 : Lilly: Financial Performance, FY 2022 and 2023

Table 87 : Lilly: Product Portfolio

Table 88 : Lilly: News/Key Developments, 2023

Table 89 : Merck & Co. Inc.: Company Snapshot

Table 90 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023

Table 91 : Merck & Co. Inc.: Product Portfolio

Table 92 : Merck & Co. Inc.: News/Key Developments, 2024

Table 93 : Novartis AG: Company Snapshot

Table 94 : Novartis AG: Financial Performance, FY 2022 and 2023

Table 95 : Novartis AG: Product Portfolio

Table 96 : Novartis AG: News/Key Developments, 2022 and 2024

Table 97 : Novo Nordisk A/S: Company Snapshot

Table 98 : Novo Nordisk A/S: Financial Performance, FY 2022 and 2023

Table 99 : Novo Nordisk A/S: Product Portfolio

Table 100 : Novo Nordisk A/S: News/Key Developments, 2022 and 2024

Table 101 : Pfizer Inc.: Company Snapshot

Table 102 : Pfizer Inc.: Financial Performance, FY 2022 and 2023

Table 103 : Pfizer Inc.: Product Portfolio

Table 104 : Pfizer Inc.: News/Key Developments, 2022

Table 105 : Teva Pharmaceutical Industries Ltd.: Company Snapshot

Table 106 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023

Table 107 : Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 108 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2023 and 2024

List of Figures

Summary Figure : Global Therapeutics for Women’s Health Technologies Market Shares, by Region, 2023

Figure 1 : Snapshot of Market Dynamics

Figure 2 : Global Therapeutics for Women’s Health Technologies Market Shares, by Women’s Health Disorder, 2023

Figure 3 : Global Breast Cancer Market in Therapeutics for Women’s Health Technologies, 2021–2029

Figure 4 : Global Breast Cancer Market in Therapeutics for Women’s Health, by Region, 2021–2029

Figure 5 : Global Postmenopausal Osteoporosis Market in Therapeutics for Women’s Health, 2021–2029

Figure 6 : Global Postmenopausal Osteoporosis Market in Therapeutics for Women’s Health, by Region, 2021–2029

Figure 7 : Global Menopause Market in Therapeutics for Women’s Health, 2021–2029

Figure 8 : Global Menopause Market in Therapeutics for Women’s Health, by Region, 2021–2029

Figure 9 : Global Endometriosis Market in Therapeutics for Women’s Health, 2021–2029

Figure 10 : Global Endometriosis Market in Therapeutics for Women’s Health, by Region, 2021–2029

Figure 11 : Global PCOS Market in Therapeutics for Women’s Health, 2021–2029

Figure 12 : Global PCOS Market in Therapeutics for Women’s Health, by Region, 2021–2029

Figure 13 : Global Therapeutics for Women’s Health Technologies Market Shares, by Region, 2023

Figure 14 : Global Therapeutics for Women’s Health Technologies Market, by Region, 2021–2029

Figure 15 : North American Therapeutics for Women’s Health Technologies Market Shares, by Country, 2023

Figure 16 : U.S. Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 17 : Canadian Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 18 : Mexican Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 19 : European Therapeutics for Women’s Health Technologies Market Shares, by Country, 2023

Figure 20 : German Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 21 : U.K. Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 22 : French Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 23 : Italian Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 24 : Spanish Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 25 : Rest of European Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 26 : Asia-Pacific Therapeutics for Women’s Health Technologies Market Shares, by Country, 2023

Figure 27 : Chinese Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 28 : Japanese Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 29 : Indian Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 30 : Australian Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 31 : South Korean Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 32 : Rest of APAC Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 33 : Rest of the World Therapeutics for Women’s Health Technologies Market, 2021−2029

Figure 34 : Snapshot of ESG Pillars

Figure 35 : Advantages of ESG for Companies

Figure 36 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2023

Figure 37 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2023

Figure 38 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2023

Figure 39 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2023

Figure 40 : Asahi Kasei Corp.: Revenue Shares, by Business Unit, FY 2023

Figure 41 : Asahi Kasei Corp.: Revenue Shares, by Country/Region, FY 2023

Figure 42 : AstraZeneca: Revenue Shares, by Business Unit, FY 2023

Figure 43 : AstraZeneca: Revenue Shares, by Country/Region, FY 2023

Figure 44 : Bayer AG: Revenue Shares, by Business Unit, FY 2023

Figure 45 : Bayer AG: Revenue Shares, by Country/Region, FY 2023

Figure 46 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023

Figure 47 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023

Figure 48 : Eisai Co. Ltd.: Revenue Shares, by Business Unit, FY 2023

Figure 49 : Eisai Co. Ltd.: Revenue Shares, by Country/Region, FY 2023

Figure 50 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023

Figure 51 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023

Figure 52 : Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2023

Figure 53 : Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2023

Figure 54 : Lilly: Revenue Shares, by Business Unit, FY 2023

Figure 55 : Lilly: Revenue Shares, by Country/Region, FY 2023

Figure 56 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2023

Figure 57 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2023

Figure 58 : Novartis AG: Revenue Shares, by Business Unit, FY 2023

Figure 59 : Novartis AG: Revenue Shares, by Country/Region, FY 2023

Figure 60 : Novo Nordisk A/S: Revenue Shares, by Business Unit, FY 2023

Figure 61 : Novo Nordisk A/S: Revenue Shares, by Country/Region, FY 2023

Figure 62 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2023

Figure 63 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2023

Figure 64 : Teva Pharmaceutical Industries Ltd.: Revenue Shares, by Country/Region, FY 2023

BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。

ライセンス別価格表

2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

新価格表

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

旧価格表

旧ライセンスタイプ1

旧ライセンスタイプ2

ご購入に関するご案内

価格・納期について

• 価格
• ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • 2-5ライセンス
    • 同一企業内5名までレポートファイルのご利用が可能です。
  • サイトライセンス
    • 同一企業同住所内でレポートファイルのご利用が可能です。
  • エンタープライズライセンス
    • 同一企業内人数無制限でレポートファイルのご利用が可能です。
• 納品形態
  • Eメール
• 納期
  • ご注文後3営業日以内

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• がん免疫療法の技術と世界市場 2025-04-17
• 再生可能エネルギーの技術と世界市場 2025-04-17
• 木材・プラスチック複合材の技術と世界市場 2025-04-17
• 先端材料の調査レビュー　2024年 2025-04-16
• コールドチェーンの地域別市場分析：中東＆北アフリカ 2025-04-16

BCC Research  出版レポート一覧